In this paper, we demonstrate key in vivo proof-of-concept data supporting our lead program, AT-108. Novel data shows that AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into antigen-presenting dendritic cells. This causes strong, antigen-specific, anti-tumor responses to be mounted, resulting in durable tumor shrinkage even upon metastatic rechallenge.
View publicationIn this paper, we demonstrate reprogramming of over 60 mouse and human tumor cells across a broad spectrum of tumor types into functional antigen-presenting cells. This study represents a significant milestone for Asgard’s reprogramming technologies, providing the foundation for the ongoing development of its in-vivo engineering programs.
The paper was featured in the 'Research Highlights' section of Nature Immunology
View publicationIn this interview, reprogramming Star Cristiana Pires unveils the career path that lead her to the stellar position of CEO and Co-founder at Asgard Therapeutics in this month issue of Cellular Reprogramming.
View publicationIn this paper, we used single-cell transcriptomics to dissect successful reprogramming of human fibroblasts into induced cDC1-like cells and improved cDC1 reprogramming efficiency by 190-fold. We benchmarked the function of induced cDC1-like cells to naturally-occuring cDC1s and explored how PU.1, IRF8 and BATF3 engage the chromatin to induce the cDC1 fate in fibroblasts.
View publicationIn this review, we summarize current strategies for cancer immunotherapy, summarize technologies for generation of immune cells by cell fate reprogramming as well as highlight the future potential of inducing these unique cell identities in vivo, providing new and exciting tools for the fast-paced field of cancer immunotherapy.
View publication